|Bid||145.75 x 100|
|Ask||150.00 x 100|
|Day's range||145.20 - 148.96|
|52-week range||96.42 - 164.76|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||173.86|
A new spin on an old drug could dent demand for Epidiolex, a marijuana-based epilepsy drug. Plus, here's how important Medicare and Medicaid are to UnitedHealth Group's profits.
Although 30 states have legalized cannabis in some capacity, the federal scheduling of pot is a major headache for businesses and medical patients.
Despite generally being a voice of opposition, seniors using medical cannabis for pain relief revealed intriguing results in a new survey.
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
GW Pharmaceuticals Plc grows about 20 tons of cannabis annually at greenhouses the size of football fields in an undisclosed corner of the English countryside. The plants, genetically modified to remove the psychoactive properties, are used to produce Epidiolex, a prescription drug for children with severe epilepsy. The U.S. Food and Drug Administration approved the treatment on June 25, making it the first prescription medicine derived from cannabis permitted to be sold in the U.S.
As Canada marches toward recreational legalization for marijuana, Canopy CEO Bruce Linton is optimistic about marketing beverages and sleep-aids to a broader audience.
The DEA must make a final scheduling decision before the drug can be soldDr. The Food and Drug Administration approved the U.S.’s first cannabis-derived drug on Monday, in a move that may make the path to approval clearer for other companies working in the space. The drug, GW Pharmaceuticals’ epidiolex, is intended for seizures associated with two rare types of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.